title: What does ALLHAT tell us about dyslipidemia from the hypertension specialist perspective?
authors.affiliation: Department of Medicine, University of Nevada School of Medicine, Renown Institute for Heart and Vascular Health, Reno, NV 89502, USA. michael@bluesprucemed.com
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Bloch
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D017035:Pravastatin / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin
references.citation: Circulation. 2004 Jul 13;110(2):227-39
references.pmid: 15249516
references.citation: N Engl J Med. 2008 Nov 20;359(21):2195-207
references.pmid: 18997196
references.citation: JAMA. 2002 Dec 18;288(23):2981-97
references.pmid: 12479763
references.citation: Arch Intern Med. 2010 Jun 28;170(12):1024-31
references.pmid: 20585067
references.citation: JAMA. 2002 Dec 18;288(23):2998-3007
references.pmid: 12479764
references.citation: Lancet. 2003 Apr 5;361(9364):1149-58
references.pmid: 12686036
references.citation: J Clin Hypertens (Greenwich). 2013 Aug;15(8):542-54
references.pmid: 23889716